Impact of routine prophylaxis with monoclonal antibodies and maternal immunisation to prevent respiratory syncytial virus hospitalisations, Lombardy region, Italy, 2024/25 season

Background Respiratory syncytial virus (RSV) is a leading cause of hospitalisation in children worldwide. Recent regulatory approval of monoclonal antibody (mAb) nirsevimab for infants and the RSVpreF vaccine for pregnant women offers promising approaches to mitigate RSV-associated morbidity. Aim To...

Ausführliche Beschreibung

Bibliografische Detailangaben

1. Verfasser:	Piero Poletti
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	European Centre for Disease Prevention and Control 2025-04-01
Schriftenreihe:	Eurosurveillance
Schlagworte:	maternally-acquired immunity transmission model respiratory syncytial virus monoclonal antibodies immunization programs respiratory syncytial virus vaccines
Online-Zugang:	https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2025.30.14.2400637
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!